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Spanish health costs database. Costs were evaluated for
the acquisition of antibiotic treatments, change of anti-
biotic due to therapeutic failure, hospital admissions,
adverse reactions treatment, primary care visits, tests and
indirect costs (working days lost). The model was vali-
dated by a panel of Spanish clinical experts. RESULTS:
As there were no signiﬁcant differences in efﬁcacy be-
tween the treatment options (clinical cure rate 88.3% and
88.5% respectively), a cost minimisation analysis was
performed. In the base case, the average cost of the
disease per patient was €308.29 with Telithromycin and
€331.5 with Clarithromycin (a difference of €23.21). The
results were stable in the sensitivity analysis, with differ-
ences favourable to Telithromycin ranging between €5.50
and €45.45. CONCLUSIONS: Telithromycin results in a
cost saving of up to €45.45 per patient with CAP com-
pared to Clarithromycin.
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OBJECTIVE: A cost-effectiveness analysis was con-
ducted, from the perspective of the Spanish National
Healthcare System, comparing sequential IV/PO moxi-
ﬂoxacin (MXF) monotherapy to standard comparators in
patients with CAP. METHODS: Costs and consequences
over 21 days were evaluated based on clinical cure rates
5–7 days post-treatment (test-of-cure (TOC) visit) and
resource use reported for the TARGET multinational,
randomized, open-label trial. Sequential IV/PO
monotherapy with MXF 400mg OD was compared to
IV/PO amoxicillin/clavulanate (AMC) (1.2g IV/625mg
PO TID) +/- clarithromycin (CLA) (500mg BID) for 7–14
days in hospitalized patients with CAP. Since the treat-
ment effect on resource use was similar across countries,
resource data from all centers were pooled and valued
using Spanish unit prices to estimate CAP-related
cost/patient to the Spanish healthcare system. RESULTS:
Clinical efﬁcacy analyses for the ITT and PP populations
found 8.3% (95% CI: 3.1, 13.6) and 8.1% (95% CI: 2.9,
13.2) higher cure rates in the MXF group at TOC. For
the economic evaluation, patients with an indeterminate
or missing outcome at TOC were assumed to be clinical
failures, resulting in higher cure rates in the MXF group
of 5.3% (95% CI 1.2%, 11.8%). A statistically signiﬁ-
cant increased speed of response (ﬁrst return to apyrexia
1 day sooner; p = 0.008) and reduction in hospital stay
by 0.81 days (95% CI: 1.63, 0.01) was observed in the
MXF group. Treatment with MXF resulted in savings of
€254/patient to the Spanish healthcare system, primarily
due to a shorter hospital stay. A cost-effectiveness accept-
ability curve demonstrated the probability of MXF being
cost saving was 90%, and the probability of MXF being
cost-effective relative to AMC ± CLA reached 94% at
acceptability thresholds up to €2000/additional patient
cured. CONCLUSION: MXF IV/PO monotherapy shows
signiﬁcant clinical outcomes and is cost-effective to the
Spanish National Healthcare System compared to IV/PO
AMC ± CLA in the treatment of CAP.
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OBJECTIVES: In a Phase-3 clinical trial we compared
hospital and outpatient antibiotic treatment costs for
MRSS patients treated with linezolid to those treated with
vancomycin. Linezolid, ﬁrst of a new class of antibiotics,
the oxazolidinones, is active against gram positive bacte-
ria sensitive and resistant to other antibiotics and is avail-
able in bioequivalent oral and IV formulations. Hospital
length of stay data from this trial (Li et al, 2001), sug-
gests linezolid use may result in earlier discharge than
vancomycin use. METHODS: Hospitalized patients with
pneumonia, skin/soft tissue infection, right-sided endo-
carditis, urinary tract infection, or bacteremia caused by
MRSS were treated with linezolid (IV/oral, n = 240) or
vancomycin (IV only, n = 220) in a randomized multi-
center clinical trial. Of the 460 intent-to-treat (ITT)
patients, 254 were clinically evaluable. Patients received
up to four weeks of treatment followed by up to four
weeks of post-treatment observation, including outpa-
tient use of study medication. Total hospital costs were
calculated using observed resource use (inpatient days by
hospital unit type, non-investigational therapies and 
medications, and study medications) and 1999 unit costs
from 8 countries, adjusted to 2001 price levels. Using a
societal perspective, total costs are compared using mean,
median and regression-adjusted (linear and log) differ-
ences. RESULTS: Mean and median total costs in the ITT
sample were higher for linezolid patients than van-
comycin patients, but no differences were statistically dif-
ferent from zero. Non-normality caused unadjusted mean
